<DOC>
	<DOCNO>NCT01773616</DOCNO>
	<brief_summary>The treatment multisystem autoimmune disease systemic lupus erythematosus ( SLE ) remain challenge , particularly renal involvement ( lupus nephritis ) . For last 60 year corticosteroids backbone treatment lupus nephritis associate significant toxicity . Although randomized placebo control trial Rituximab non-renal lupus lupus nephritis meet primary end-points , accumulate data suggest B cell depletion Rituximab may efficacious lupus disease refractory conventional therapy . Furthermore , pilot data suggest addition Rituximab mycophenolate mofetil ( MMF ) without oral steroid least effective induce renal response standard care therapy comprise MMF high dose oral corticosteroid . RITUXILUP proof concept , open label , randomize , control , multicentre trial aim demonstrate whether addition Rituximab MMF therapy useful treat new flare lupus nephritis whether long lasting steroid-sparing , beneficial effect equal efficacy great safety conventional regimen MMF oral prednisolone . If successful , trial potential dramatically change management lupus nephritis .</brief_summary>
	<brief_title>Trial Rituximab Mycophenolate Mofetil Without Oral Steroids Lupus Nephritis</brief_title>
	<detailed_description>TRIAL SUMMARY TITLE RITUXILUP - An open label randomise multicentre control trial RITUXImab mycophenolate mofetil ( MMF ) without oral steroid treatment LUPus nephritis OBJECTIVES 1 . Is combination Rituximab , Methyl prednisolone MMF effective treat lupus nephritis Methyl prednisolone , oral steroid MMF ? 2 . Does omission oral steroid increase safety treatment regimen ? DESIGN This 1:1 randomise , international open label , control phase III multicentre trial SAMPLE SIZE A total 252 patient : 126 patient arm ELIGIBILITY Children ( 12 year ) adults lupus nephritis ISN/RPS Class III A A/C , Class IV-G A A/C , Class IV-S A A/C , and/or Class V urine protein/creatinine ratio ( PCR ) â‰¥ 100mg/mmol . TREATMENT 1 . Experimental group - Rituximab , IV methyl prednisolone mycophenolate mofetil 2 . Control group - oral prednisolone , IV methyl prednisolone mycophenolate mofetil . PRIMARY OUTCOME The primary outcome demonstrate non-inferiority Rituximab arm comparison control arm proportion patient achieve complete renal response ( CR ) week 52 without need steroid prescription . SECONDARY OUTCOMES Safety outcome : - Serious Infectious Episodes - Serious Adverse Events - Evidence metabolic abnormality particularly new onset diabetes Disease control time : - Proportion patient achieve Partial Response ( PR ) - Time stable CR - Time PR - Proportion patient PR achieve histological remission repeat biopsy part local standard care - Proportion patient renal extra flare - Cumulative steroid exposure - Deviation steroid taper steroid arm and/or introduction steroid steroid-free arm - Proportion patient achieve response define SLE Responder Index ( SRI ) week 52 annually thereafter define : - &gt; 4 point reduction SELENA-SLEDAI score ; - new BILAG A organ domain score ; - I new BILAG B score ; - worsen physician 's global assessment ( PGA ) &gt; 10 % ; - must receive non-protocol treatment . - Proportion patient achieve response define BILAG-based Composite Lupus Assessment ( BICLA ) week 52 annually thereafter define : BILAG-2004 improvement ( BILAG A B/C/D , BILAG B C/D BILAG worsening , deterioration SLEDAI total score , worsen physician 's global assessment ( PGA ) &gt; 10 % must receive non-protocol treatment .</detailed_description>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Nephritis</mesh_term>
	<mesh_term>Lupus Nephritis</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Inclusion criterion : 1 . Adults age 1875 year old child age 1217 year old . 2 . Active lupus nephritis , define kidney biopsy within prior 8 week assess International Society Nephrology/Renal Pathology Society ( ISN/RPS ) classification : 1. class III ( A A/C ) active lesion least 20 % viable glomerulus , 2. class IVS ( A A/C ) active lesion least 20 % viable glomerulus , 3. class IVG ( A A/C ) active lesion least 20 % viable glomerulus / 4. class V 5. urine proteintocreatinine ratio &gt; 100mg/mmol ( &gt; 1mg/mg ) visit 1 time within 14 day visit 1 3 . No contraindication use IV methyl prednisolone , MMF , oral steroid rituximab require medication antipyretic , antihistamine 4 . Ability provide inform consent 5 . Willing use appropriate contraception female risk pregnancy ( progesterone pill , progesterone implant , combine oral contraceptive contraindicate , intrauterine contraceptive device , barrier method ) Exclusion criterion : 1 . Obsolescence &gt; 50 % glomeruli tubulointerstitial scar &gt; 50 % 2 . Severe `` critical '' SLE flare define : 1 . BILAG 2004 A flare CNS system 2. SLE manifestation require immunosuppression allow within protocol physician 's opinion 3 . Pregnancy 4 . Breast feed 5 . Patients willing GP inform participation study 6 . Patients require maintenance steroid 4 week steroids period immediately precede recruitment irrespective dose 7 . Patients receive 1.5g IV methyl prednisolone previous 4 week 8 . Prior use within 12 month visit 1 therapeutic monoclonal antibody , B T cell modulate 'biologic ' use 9 . Prior use within 6 month visit 1 Intravenous immunoglobulin / plasma exchange OR Cyclophosphamide 10. eGFR &lt; 30mls/min/1.73m2 11 . Active infection , include limited human immunodeficiency virus ( HIV ) , hepatitis B ( include prior infection judge positive Hepatitis B core antibody ) Hepatitis C tuberculosis 12 . Receipt liveattenuated vaccine within 3 month study enrolment 13 . In investigator 's opinion , patient high risk infection ( include limit indwelling catheter , dysphagia aspiration , decubitus ulcer , history prior aspiration pneumonia recurrent severe urinary tract infection ) 14 . Prior history invasive fungal infection 15 . History cancer 16 . In female patient , know history cervical dysplasia CIN Grade III cervical high risk human papillomavirus abnormal cervical cytology abnormal squamous cell undetermined significance ( ASCUS ) within past 3 year . The patient eligible condition resolve ( e.g. , followup HPV test negative cervical abnormality effectively treat &gt; 1 year ago ) 17 . Any concomitant medical condition investigator 's opinion , discussion CI , place participant risk participate study . 18 . Comorbidities require systemic corticosteroid therapy . 19 . Current substance abuse . 20 . IgG low limit local laboratory range</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Systemic lupus erythematosus</keyword>
	<keyword>Lupus</keyword>
	<keyword>Nephritis</keyword>
</DOC>